[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.213.148. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1959

The Use of Dexamethasone in Ophthalmologic Steroid TherapyA Preliminary Report

Author Affiliations

North Hollywood, Calif.

AMA Arch Ophthalmol. 1959;62(3):438-444. doi:10.1001/archopht.1959.04220030094014
Abstract

As experience has taught us, the biologic properties of cortisone and hydrocortisone may be altered, both favorably and unfavorably, through changes in their basic structure. The unending search to build better clinical properties into adrenocortical steroids appears to have moved an important step ahead with the synthesis of dexamethasone, achieved by addition of a methyl radical at carbon 16 and a fluorine atom at carbon 9 of the prednisolone structure.1,2 Preliminary observations indicate that the alteration to produce dexamethasone certainly has resulted in an improved compound with greatly increased milligram activity along with substantially decreased undesirable effects.

Initial studies with dexamethasone revealed that this compound has a milligram activity approximately 8-10 times that of prednisone or prednisolone and 30 times that of cortisone. Certain undesirable effects reported with the hydroxylated steroids (such as triamcinolone) of muscle wasting, increased tendency to ecchymoses, and abnormal weight loss are not associated with

First Page Preview View Large
First page PDF preview
First page PDF preview
×